Sugi Predict

Sugi Predict / Compounds / SCHEMBL17427751

SCHEMBL17427751

SCHEMBL17427751

COC(=O)N(C)c1ccc(B2OC(C)(C)C(C)(C)O2)cc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK1 Q13464 1/20 0.42
▸ BACE1 P56817 1/20 0.40
▸ BACE2 Q9Y5Z0 1/20 0.40
▸ LIPG Q9Y5X9 3/20 0.39
▸ LPL P06858 2/20 0.39
▸ DGAT1 O75907 1/20 0.37
▸ HIF1A Q16665 3/20 0.37
▸ CSF1R P07333 1/20 0.36
▸ CA1 P00915 4/20 0.36
▸ CA2 P00918 4/20 0.36
▸ CA9 Q16790 4/20 0.36
▸ F2 P00734 1/20 0.36
▸ F11 P03951 1/20 0.36
▸ PRSS1 P07477 1/20 0.36
▸ PRSS2 P07478 1/20 0.36
▸ PRSS3 P35030 1/20 0.36
▸ CA12 O43570 1/20 0.35
▸ CA3 P07451 1/20 0.35
▸ CA4 P22748 1/20 0.35
▸ CA6 P23280 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14241986 0.86 BACE1 (0.51) ROCK1BACE1BACE2LIPGLPL
SCHEMBL17423909 0.85 ROCK1 (0.45) ROCK1BACE1BACE2LIPGLPL
SCHEMBL17419144 0.83 HIF1A (0.40) ROCK1BACE1BACE2LIPGLPL
SCHEMBL17419180 0.79 ROCK1 (0.50) ROCK1BACE1BACE2LIPGLPL
SCHEMBL13718426 0.79 LPL (0.49) ROCK1BACE1BACE2LIPGLPL
SCHEMBL19510675 0.79 ROCK1 (0.41) ROCK1BACE1BACE2LIPGLPL
SCHEMBL17419130 0.78 CA1 (0.43) LIPGLPLDGAT1CA1CA2
SCHEMBL516413 0.76 ROCK1 (0.46) ROCK1BACE1BACE2LIPGLPL
SCHEMBL30004376 0.76 ROCK1 (0.46) ROCK1BACE1BACE2LIPGLPL
SCHEMBL20660833 0.76 ROCK1 (0.40) ROCK1BACE1BACE2LIPGLPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200392143-A1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS INCYTE CORPORATION 2020-12-17 — — US disclosed
US-10800779-B2 Heterocyclic compounds as LSD1 inhibitors INCYTE CORPORATION (US) 2020-10-13 — — US disclosed
US-10640503-B2 Imidazopyridines and imidazopyrazines as LSD1 inhibitors INCYTE CORPORATION (US) 2020-05-05 — — US disclosed
EP-3626720-A1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS Incyte Corporation (US) 2020-03-25 — — EP disclosed
EP-3277689-B1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS INCYTE CORP (US) 2019-09-04 — — EP disclosed
US-20190055250-A1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS INCYTE CORPORATION 2019-02-21 — — US disclosed
US-20190040058-A1 IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION 2019-02-07 — — US disclosed
US-9944647-B2 Heterocyclic compounds as LSD1 inhibitors INCYTE CORPORATION (US) 2018-04-17 — — US disclosed
US-9944647-B2 Heterocyclic compounds as LSD1 inhibitors INCYTE CORPORATION (US) 2018-04-17 — — US disclosed
US-20170369487-A1 IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION 2017-12-28 — — US disclosed
US-9695168-B2 Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors INCYTE CORPORATION (US) 2017-07-04 — — US disclosed
US-9695168-B2 Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors INCYTE CORPORATION (US) 2017-07-04 — — US disclosed
WO-2016161282-A1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS INCYTE CORPORATION (US) 2016-10-06 — — WO disclosed
US-20160289238-A1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS INCYTE CORPORATION 2016-10-06 — — US disclosed
US-20160289238-A1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS INCYTE CORPORATION 2016-10-06 — — US disclosed
US-20160009712-A1 IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION 2016-01-14 — — US disclosed
WO-2016007731-A1 IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION (US) 2016-01-14 — — WO disclosed
US-20160009712-A1 IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION 2016-01-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200392143-A1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS KDM1B, KDM1A, DOT1L ROCK1 1257/4885BACE1 1732/4885BACE2 2543/4885
US-20170369487-A1 IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS KDM5A, KDM1A, KDM1B ROCK1 832/4885BACE1 3368/4885BACE2 4435/4885
US-20190055250-A1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS KDM1B, KDM1A, DOT1L ROCK1 1257/4885BACE1 1732/4885BACE2 2543/4885
US-20190040058-A1 IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS KDM5A, KDM1A, KDM1B ROCK1 832/4885BACE1 3368/4885BACE2 4435/4885
US-20160009712-A1 IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS KDM5A, KDM1A, KDM1B ROCK1 1686/4885BACE1 2997/4885BACE2 3926/4885
US-20160289238-A1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS KDM1B, KDM1A, DOT1L ROCK1 1257/4885BACE1 1732/4885BACE2 2543/4885
US-10800779-B2 Heterocyclic compounds as LSD1 inhibitors KDM1B, KDM1A, DOT1L ROCK1 1257/4885BACE1 1732/4885BACE2 2543/4885
US-10640503-B2 Imidazopyridines and imidazopyrazines as LSD1 inhibitors KDM5A, KDM1A, KDM1B ROCK1 832/4885BACE1 3368/4885BACE2 4435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.